VivoSeq
Oncology

Pediatric Cancer

25

Pipeline Programs↗

7

Active Trials↗

15

Companies Involved↗

Pediatric Cancer is an emerging landscape with 25 programs across 15 companies. The most active players are AstraZeneca, Novartis, Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

6/100

Mech. Concentration

12/100

Completion Rate

88/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

7 programs

PreclinicalNovartis logo

Novartis

3 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

PreclinicalPfizer logo

Pfizer

1 program

PreclinicalM

Meitheal

1 program

PreclinicalC

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

84%

Small molecule

21 of 25 classified programs — the dominant modality here.

16%ALL OTHERSMonoclonal antibody416%

Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 100% of 25 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed7 · 41%
Recruiting5 · 29%
Unknown status2 · 12%
Terminated1 · 6%
Active, not recruiting1 · 6%
Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

Engineering Immune Organoids to Study Pediatric Cancer
Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·N/A·NCT05890781·108 enrolled
Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with Chemotherapy
Recruiting·SSun Yat-sen University·Phase 2·NCT06857292·97 enrolled
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
Recruiting·—·Phase 2·NCT06088030·50 enrolled
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Preclinical·NCT02813135·472 enrolled
Psychological Benefits of a Normalized Camping Experience for Children With Cancer
Recruiting·National Cancer Institute (NCI)·N/A·NCT00001186·5,000 enrolled
Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or in Combination With Tremelimumab in Pediatric Patients With Advanced Solid Tumors and Hematological Malignancies.
Active, not recruiting·AstraZeneca logoAstraZeneca·Preclinical·NCT03837899·50 enrolled
Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients
Not yet recruiting·WWake Forest University Health Sciences·Preclinical·NCT06744712·130 enrolled
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Completed·—·Phase 1·NCT03654716·21 enrolled
Pharmacokinetics of Itraconazole in Pediatric Cancer Patients
Completed·SSeoul National University Hospital·Phase 1·NCT01409018·6 enrolled
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Completed·—·Phase 1·NCT03936465·41 enrolled
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
Completed·Pfizer logoPfizer·Phase 2·NCT00952380·38 enrolled
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
Completed·Sanofi logoSanofi·Phase 1/2·NCT01288573·46 enrolled
Feasibility and Safety of Acupuncture With Semi-Permanent Needles for the Prevention of Irinotecan-Associated Diarrhea in Pediatric Solid Tumors: A Prospective Pilot Study
Completed·FFundació Sant Joan de Déu·Preclinical·NCT05507736·22 enrolled
Buzzy®, a Cognitive-Behavioral Intervention Package, and a Kaleidoscope for Reducing Pain, Fear, and Anxiety During Subcutaneous Injections in Children With Cancer: A Three-Arm Randomized Controlled Trial
Completed·KKocaeli University·Preclinical·NCT07667712·45 enrolled
Phase I/II Study of Avelumab in Pediatric Cancer Participants
Terminated·EMD Serono Research & Development Institute, Inc. logoEMD Serono Research & Development Institute, Inc.·Phase 1·NCT03451825·21 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)